Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
CONCLUSION: Based on the common willingness-to-pay threshold of SGD 50,000/QALY, this study demonstrates the cost-effectiveness of WVTT over MM as first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL is not cost-effective as first- nor second-line treatment. For patients with severe BPH, TURP as first-line is also cost-effective.PMID:37800562 | DOI:10.1080/13696998.2023.2266958 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 6, 2023 Category: Health Management Authors: Junxing Chay Joshua Yi Min Tung Rebecca Jade Su Edwin Jonathan Aslim Callix Wong Georgia Swan Wei Jin Chua Henry Sun Sien Ho Eric Andrew Finkelstein Source Type: research
Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension
Conclusions: OS use over two years would result in lower total, drug, and hospitalization-related costs compared with OT, thus providing financial savings for payers.PMID:37800591 | DOI:10.1080/13696998.2023.2254160 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 6, 2023 Category: Health Management Authors: John McConnell S Pinar Bilir Yifan Xu Yuen Tsang Sumeet Panjabi Source Type: research
Healthcare resource utilization and costs for patients with postoperative atrial fibrillation in the United States
CONCLUSION: POAF following open-heart surgery poses a significant economic burden up to 1 year postdischarge.PMID:37801391 | DOI:10.1080/13696998.2023.2267390 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 6, 2023 Category: Health Management Authors: Tae Jin Park Ryan Hansen Patrick Gillard Darshini Shah William G Ferguson Jonathan Piccini Matthew A Romano Beth Devine Source Type: research
Correction
J Med Econ. 2023 Jan-Dec;26(1):1212-1213. doi: 10.1080/13696998.2023.2265633. Epub 2023 Oct 6.NO ABSTRACTPMID:37802988 | DOI:10.1080/13696998.2023.2265633 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 6, 2023 Category: Health Management Source Type: research
Cost-effectiveness of left atrial appendage closure with watchman for non-valvular atrial fibrillation patients in Japan. Are the policy implications big in Japan?
J Med Econ. 2023 Oct 5:1-4. doi: 10.1080/13696998.2023.2267392. Online ahead of print.NO ABSTRACTPMID:37794807 | DOI:10.1080/13696998.2023.2267392 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 5, 2023 Category: Health Management Authors: Panagiotis Petrou Source Type: research
